News >

Ropeginterferon Alfa-2b Demonstrates Durable Activity in Polycythemia Vera

Published: Thursday, Dec 21, 2017

Heinz Gisslinger, MD

Heinz Gisslinger, MD

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response (CHR) versus hydroxyurea (Hydrea) in patients with polycythemia vera (PV).1

The reduction in JAK2 allele burden increased over time with ropeginterferon alfa-2b, whereas hyaluronic acid achieved greater reductions early in the course of treatment and the effect declined over time.

References

  1. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial. Presented at: 2017 ASH Annual Meeting; December 9-12, 2017; Atlanta, GA. Abstract 320.
  2. Gisslinger H, Klade C, Georgiev P, et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Presented at: 2016 ASH Annual Meeting; December 3-6, 2016; San Diego, CA. Abstract 475.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x